EMV Capital, the venture Investment group quoted on the FTSE AIM All Share Index, has changed its key market advisers. On 9 November 2026 the company announced that Grant Thornton UK Advisory & Tax LLP had been appointed as its nominated adviser and Shore Capital Stockbrokers Limited as its broker, both with immediate effect. The move follows interim results in September that showed a sharp rise in net asset value per share, largely driven by an accounting change.

What the company does

EMV Capital invests in and supports early-stage technology and life sciences businesses, and manages funds on behalf of other investors. Its core operations earn Revenue from value creation services and corporate finance fees, alongside the potential for gains on its own holdings. Portfolio companies named in recent announcements include Glycotest, ProAxsis and AMR Bio, as well as a newly added Business that acquired a recycling plant in September 2026.

Latest developments

The adviser change is the most recent formal announcement. A nominated adviser is required for every AIM company, and changes of this kind can sometimes accompany a shift in strategy or simply reflect a review of service providers. The company also Issued Shares in early November, in an announcement covering a dealing by a person discharging managerial responsibilities and an update to total voting rights.

On 13 October 2026, EMV Capital reported that portfolio company Glycotest had taken an exclusive worldwide licence to intellectual property from the Medical University of South Carolina. Glycotest is developing a blood test to stage liver fibrosis, and the licensed biomarker is intended to strengthen its existing approach by combining markers into panels. The licence includes royalties and other financial terms for the university, though no figures were disclosed.

Financial and Dividend picture

Interim results for the six months to 30 June 2026, released on 24 September, reported Assets under management of £117.5 million, up from £112.5 million at the end of 2025. Net assets were £33.4 million and net asset value per share rose 145% to £1.20. That increase was largely due to the deconsolidation of Glycotest and ProAxsis, which generated a non-cash gain of £25.1 million. As a result the group reported a profit of £17.8 million, but the underlying result was a net loss of £2.1 million.

Revenue from EMV Capital's core operations rose 9% to £1.5 million. Cash at the period end was £0.7 million, a modest figure relative to the size of the portfolio. No dividend was reported.

Sector and index context

Listed venture and investment groups on AIM often trade at a discount to stated asset values, reflecting the difficulty of valuing unquoted holdings and uncertainty over the timing of exits. EMV Capital sits within the financial and investment segment of the FTSE AIM All Share Index, where sentiment toward early-stage healthcare and deep technology investment can shift quickly with funding conditions.

Key risks

The largest gains in the interim period were non-cash, so the headline profit does not indicate cash generation. Portfolio valuations depend on assumptions about businesses that may not yet be profitable, and realising value usually requires further funding rounds or sales. The low cash balance at the half-year means the group's financial flexibility is limited.

What to watch next

Investors will look for evidence that the new advisory team brings fresh corporate activity, and for further progress at Glycotest, ProAxsis and AMR Bio. Any exits, fund raises or updates on assets under management will be important, ahead of full-year results for 2026; results for 2025 were published in May this year.